Erratum to Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure [Toxicological Sciences, 131, 1 (2013) 259-270] doi:10.1093/toxsci/kfs274;Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure

Toxicological Sciences

Volumn 131, Issue 1, 2013, Pages 259-270

  Fretellier, Nathalie ^a,b   Bouzian, Nejma ^a   Parmentier, Nadège ^a   Bruneval, Patrick ^c   Jestin, Gaëlle ^a   Factor, Cécile ^a   Mandet, Chantal ^c   Daubiné, Florence ^d   Massicot, France ^b   Lapévote, Olivier ^b,e   Hollenbeck, Claire ^a   Port, Marc ^a   Idée, Jean Marc ^a   Corot, Claire ^a  

^a Laboratoire Guerbet   (France)

^b FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d Atlantic Bone Screen   (France)

^e HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Contrast agents; Gadolinium; Magnetic resonance imaging; Nephrogenic systemic fibrosis; Relaxometry; Renal impairment

Indexed keywords

ADENINE; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM CHELATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIC ACID; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SODIUM CHLORIDE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DERMATITIS; DIETARY INTAKE; DISEASE ASSOCIATION; DISSOCIATION; HISTOPATHOLOGY; IN VIVO STUDY; KIDNEY FAILURE; MALE; MASS SPECTROMETRY; MORTALITY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; RAT; RELAXOMETRY; SKIN BIOPSY; SKIN CALCIFICATION; SKIN FIBROSIS;

RATTUS; RATTUS NORVEGICUS;

EID: 84872404959     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft004     Document Type: Erratum

References (35)

1. Abu-Alfa, A. K. (2011). Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv. Chronic Kidney Dis. 18, 188-198.
2. Caravan, P., Ellison, J. J., McMurry, T. J., and Lauffer, R. B. (1999). Gadolinium(III) chelates as MRI contrast agents: Structure, dynamics, and applications. Chem. Rev. 99, 2293-2352.
3. Coladonato, J. A. (2005). Control of hyperphosphatemia among patients with ESRD. J. Am. Soc. Nephrol. 16(Suppl. 2), S107-S114.
4. Cowper, S. E., Rabach, M., and Girardi, M. (2008). Clinical and histological findings in nephrogenic systemic fibrosis. Eur. J. Radiol. 66, 191-199.
5. Crissman, J. W., Goodman, D. G., Hildebrandt, P. K., Maronpot, R. R., Prater, D. A., Riley, J. H., Seaman, W. J., and Thake, D. C. (2004). Best practices guideline: Toxicologic histopathology. Toxicol. Pathol. 32, 126-131.
6. Frenzel, T., Lengsfeld, P., Schirmer, H., Hütter, J., and Weinmann, H. J. (2008). Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest. Radiol. 43, 817-828.
7. Fretellier, N., Idée, J. M., Guerret, S., Hollenbeck, C., Hartmann, D., González, W., Robic, C., Port, M., and Corot, C. (2011a). Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest. Radiol. 46, 85-93.
8. Fretellier, N., Idée, J. M., Dencausse, A., Karroum, O., Guerret, S., Poveda, N., Jestin, G., Factor, C., Raynal, I., Zamia, P., et al. (2011b). Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: A relaxometry study. Invest. Radiol. 46, 292-300.
9. Fretellier, N., Idée, J., Bruneval, P., Guerret, S., Daubiné, F., Jestin, G., Factor, C., Poveda, N., Dencausse, A., Massicot, F., et al. (2012). Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Br. J. Pharmacol. 165(4b), 1151-1162.
10. Galan, A., Cowper, S. E., and Bucala, R. (2006). Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr. Opin. Rheumatol. 18, 614-617.
11. Girardi, M., Kay, J., Elston, D. M., Leboit, P. E., Abu-Alfa, A., and Cowper, S. E. (2011). Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations. J. Am. Acad. Dermatol. 65, 1095-1106.e7.
12. Grant, D., Johnsen, H., Juelsrud, A., and Løvhaug, D. (2009). Effects of gadolinium contrast agents in naïve and nephrectomized rats: Relevance to nephrogenic systemic fibrosis. Acta Radiol. 50, 156-169.
13. Grobner, T. (2006). Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol. Dial. Transplant. 21, 1104-1108.
14. Haylor, J., Dencausse, A., Vickers, M., Nutter, F., Jestin, G., Slater, D., Idee, J. M., and Morcos, S. (2010). Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Invest. Radiol. 45, 507-512.
15. High, W. A., Ranville, J. F., Brown, M., Punshon, T., Lanzirotti, A., and Jackson, B. P. (2010). Gadolinium deposition in nephrogenic systemic fibrosis: An examination of tissue using synchrotron x-ray fluorescence spectroscopy. J. Am. Acad. Dermatol. 62, 38-44.
16. Idée, J. M., Port, M., Medina, C., Lancelot, E., Fayoux, E., Ballet, S., and Corot, C. (2008). Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: A critical review. Toxicology 248, 77-88.
17. Idée, J. M., Port, M., Dencausse, A., Lancelot, E., and Corot, C. (2009). Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: An update. Radiol. Clin. North Am. 47, 855-69, vii.
18. Jiménez, S. A., Artlett, C. M., Sandorfi, N., Derk, C., Latinis, K., Sawaya, H., Haddad, R., and Shanahan, J. C. (2004). Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): Study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 50, 2660-2666.
19. Kelly, B., Petitt, M., and Sanchez, R. (2008). Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement. J. Am. Acad. Dermatol. 58, 1025-1030.
20. Kelly, B. C., Markle, L. S., Vickers, J. L., Petitt, M. S., Raimer, S. S., and McNeese, C. (2010). The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis. J. Am. Acad. Dermatol. 63, 483-489.
21. Koeda, T., Wakaki, K., Koizumi, F., Yokozawa, T., and Oura, H. (1988). Early changes of proximal tubules in the kidney of adenine-ingesting rats, with special reference to biochemical and electron microscopic studies. Nihon Jinzo Gakkai Shi 30, 239-246.
22. Laurent, S., Elst, L. V., Copoix, F., and Muller, R. N. (2001). Stability of MRI paramagnetic contrast media: A proton relaxometric protocol for transmetallation assessment. Invest. Radiol. 36, 115-122.
23. Li, J. X., Liu, J. C., Wang, K., and Yang, X. G. (2010). Gadolinium-containing bioparticles as an active entity to promote cell cycle progression in mouse embryo fibroblast NIH3T3 cells. J. Biol. Inorg. Chem. 15, 547-557.
24. Lorusso, V., Arbughi, T., Tirone, P., and de Haën, C. (1999). Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). J. Comput. Assist. Tomogr. 23(Suppl. 1), S181-S194.
25. Morcos, S. K. (2008). Extracellular gadolinium contrast agents: Differences in stability. Eur. J. Radiol. 66, 175-179.
26. Newton, B. B., and Jiménez, S. A. (2009). Mechanism of NSF: New evidence challenging the prevailing theory. J. Magn. Reson. Imaging 30, 1277-1283.
27. Okada, H., Kaneko, Y., Yawata, T., Uyama, H., Ozono, S., Motomiya, Y., and Hirao, Y. (1999). Reversibility of adenine-induced renal failure in rats. Clin. Exp. Nephrol. 3, 82-88.
28. Pietsch, H., Lengsfeld, P., Steger-Hartmann, T., Löwe, A., Frenzel, T., Hütter, J., and Sieber, M. A. (2009). Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest. Radiol. 44, 226-233.
29. Port, M., Corot, C., Violas, X., Robert, P., Raynal, I., and Gagneur, G. (2005). How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo: The concept of dynamic relaxivity. Invest. Radiol. 40, 565-573.
30. Port, M., Idée, J. M., Medina, C., Robic, C., Sabatou, M., and Corot, C. (2008). Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: A critical review. Biometals 21, 469-490.
31. Rodby, R. A. (2011). Can gadolinium be given safely to a patient on dialysis? Semin. Dial. 24, 370-371.
32. Sieber, M. A., Lengsfeld, P., Frenzel, T., Golfier, S., Schmitt-Willich, H., Siegmund, F., Walter, J., Weinmann, H. J., and Pietsch, H. (2008). Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur. Radiol. 18, 2164-2173.
33. Sieber, M. A., Steger-Hartmann, T., Lengsfeld, P., and Pietsch, H. (2009). Gadolinium-based contrast agents and NSF: Evidence from animal experience. J. Magn. Reson. Imaging 30, 1268-1276.
34. Thomsen, H. S. (2011). Contrast media safety-an update. Eur. J. Radiol. 80, 77-82.
35. Yokozawa, T., Zheng, P. D., Oura, H., and Koizumi, F. (1986). Animal model of adenine-induced chronic renal failure in rats. Nephron 44, 230-234.